Immatics

XPRESIDENT

Mass spectrometry-based target discovery and characterization platform for identifying tumor-specific intracellular targets presented as peptides on cell surface via HLA molecules; integrates high-throughput mass spectrometry with genome, proteome and transcriptome data; focus: oncology (solid tumors, multiple cancer indications); expandable to HLA class II and autoimmune diseases

XCEPTOR

Proprietary TCR discovery, characterization, optimization and engineering platform for development of cell therapy and bispecific product candidates with high affinity and specificity for pHLA targets; guided by XPRESIDENT peptide target database; focus: oncology (solid tumors)

XCUBE

AI-powered in silico immunoinformatics platform integrating multi-dimensional biological data from XPRESIDENT and XCEPTOR to transform large-scale target and TCR datasets into actionable therapeutic knowledge; focus: oncology

ACTallo

Proprietary off-the-shelf allogeneic cell therapy platform adaptable across different T-cell subtypes from healthy donors, including gamma-delta T cells; designed to eliminate personalized manufacturing and enable scalable multi-dose production; focus: next-generation CAR and TCR T-cell therapies in oncology

TCER

TCR bispecific (TCER) platform — half-life extended, off-the-shelf antibody-like biologics that redirect T cells to cancer cells via a high-affinity TCR domain and a low-affinity CD3/TCR-recruiter domain; designed for solid tumor indications including lung cancer, head and neck cancer, and melanoma

Targets: MAGEA4/8, PRAME, CD3